Abbvie

72 results

Shire shareholders deserve a higher price than US drugmaker AbbVie is offering, given the company’s growth prospects, Shire’s chief executive officer (...)

Abbvie’s raised outlook came on the same day that Shire issued its own stand-alone growth plan

Biopharmaceutical firm AbbVie, which is trying to buy London-listed peer Shire, on Monday raised its 2014 adjusted earnings forecast, citing strong “b(...)

Founded in 1986 in Britain, Shire conducts most of its business in the United States and has been domiciled in Ireland for tax purposes since 2008. Photograph: JB Reed/Bloomberg News

US drugmaker AbbVie Inc has confirmed today that it had made a bid approach to Shire , which was rejected by the British group’s board. It said talks (...)

Tablets of Shire’s Adderall  are arranged in a Cambridge, Massachusetts pharmacy. The London-listed drugmaker has hired investment bank Citi as an adviser, expecting to receive takeover approaches. Photo: Bloomberg

London-listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the (...)

 Merck, the second-biggest US drugmaker, agreed to buy Idenix Pharmaceuticals for about $3.85 billion. Photo: Bloomberg

Merck, the second-biggest US drugmaker, agreed to buy Idenix Pharmaceuticals for about $3.85 billion to expand its experimental pipeline for hepatiti(...)

Biopharmaceutical firm AbbVie has opened an upgraded manufacturing facility in Co Sligo, which is expected to generate 175 new jobs when fully operati(...)

Hepatitis C virus. Photograph: Getty Images

New combination treatments that can cure the vast majority of hepatitis C patients could be available to Irish patients within(...)

Pharmaceuticals made by Actavis, one of the defendants in the lawsuits brought by the US Federal Trade Commission. Photograph: Justin Sullivan/Getty Images

The US Federal Trade Commission is seeking a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale o(...)

 Lower taxes and cost-cutting also helped Abbott beat earnings forecasts, analysts said. The company’s shares jumped 4.5 per cent in early trading to $35.23. Photographer: Tim Boyle/Bloomberg

Abbott Laboratories reported higher-than-expected quarterly earnings today, helped by strong demand for its diagnostics, and boosted its quarterly div(...)

Abbott’s second-quarter earnings were better than expected amid strong demand for nutritional products.

Abbott Laboratories reported better-than-expected second-quarter earnings today as strong demand for nutritional products offset lower sales of medica(...)

  • « First
  • Prev
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • Last »